Lung Cell Flexibility, Genetic Risk Across Populations, and Our Solver's Best Formula Yet: IPF Week of Oct 19 to 26, 2026
October 19 to 26, 2026 · Active week
This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.
The week in plain words
Twelve new research papers published this week, covering everything from genetics to diagnostic tools. No new clinical trials opened and no existing trials changed status. Our own PF-Atlas discovery engine ran its solver and produced its highest-scoring experimental drug combination to date, a five-drug cocktail that exists only as a computer-generated hypothesis so far. IPF still has no cure, but the science keeps moving.
Where things stand now
IPF remains an incurable disease. The scarring it causes in the lungs cannot be undone by any currently available treatment. Two approved drugs, pirfenidone and nintedanib, have been available for years and can slow the disease. A newer approved option, Nerandomilast (brand name Jascayd), received FDA approval in October 2025 and works by calming inflammation and reducing the activation of scar-forming cells. It slows progression but does not reverse existing damage. Inhaled Treprostinil (Tyvaso) completed Phase III trials and an FDA filing is expected in 2026. Admilparant is still in Phase III trials. All three of these are in the top tier of evidence. Several experimental approaches, including a TNIK inhibitor called Rentosertib and a CAR-T cell therapy targeting old, worn-out cells, are being studied in humans but are not proven treatments yet. Regeneration of lung tissue remains a research goal, not something doctors can offer patients today.
The best option right now
For someone living with IPF right now, the honest picture is this: no treatment cures or reverses the disease. The best available option is to work with a pulmonologist (a lung specialist) to choose from the FDA-approved anti-fibrotic drugs. Nerandomilast (Jascayd), approved in October 2025, is the newest approved drug and targets a specific pathway called PDE4B that drives scarring and inflammation. Like all approved IPF drugs, it is designed to slow how fast the scarring spreads, not to undo scarring that already exists. Inhaled Treprostinil showed strong Phase III results and may offer additional benefit, particularly for patients who also have high blood pressure in their lung blood vessels, but it is not yet fully approved for IPF. Admilparant is still being tested in its Phase III trial called ALOFT-IPF and is not yet available outside of that trial. Any decision about treatment should be made with a specialist who knows the individual patient's full picture.
How close are we to regeneration
Regrowing or repairing scarred lung tissue is the long-term dream of IPF research, but it is not something medicine can do today. Three experimental approaches are being explored at the earliest stages. First, uPAR-CAR-T therapy uses specially engineered immune cells to seek out and destroy old, damaged cells that fuel scarring. This has shown promise in animal studies at Memorial Sloan Kettering but has not been tested in humans yet. Second, a combination approach pairs drugs called senolytics (which clear out those same worn-out cells) with a molecule called RSPO3, which is meant to help the lung's own stem cells multiply and rebuild tissue. This is still a concept being tested in the lab. Third, AI systems are being used to map connections between IPF, aging, cancer, and other diseases to find overlooked repair mechanisms. None of these are available as treatments. Regeneration is where researchers want to go, and this week's study of the week (see below) adds an interesting new clue about how lung cells can change their identity, which is directly relevant to this goal.
Study of the week
The standout paper this week comes from Yang, Mou, Li and colleagues, published in the journal Developmental Cell. The study looks at mesothelial cells, a type of cell that normally lines the outside of the lungs, a bit like a thin wrapper. The researchers found that these cells are much more flexible than previously thought. Under certain conditions, they can change their identity and behavior, a process scientists call plasticity. This flexibility turns out to play an important role in keeping the mechanical properties of the lung stable, meaning how the lung stretches and springs back with each breath. Crucially, the study found this same flexibility is also involved in fibrosis, the scarring process. Why does this matter? If scientists can understand exactly how and why these cells switch behavior, they might eventually find a way to steer them toward repair rather than scarring. This is still basic science, not a treatment, but it adds a valuable new piece to the puzzle of why IPF happens and hints at a potential target for future regeneration research.
What changed since last week
Nothing changed in the clinical trial landscape this week. No new trials opened and no existing trials updated their status. The 12 new papers add to the scientific knowledge base but do not shift the overall treatment picture. The field is in a steady research phase rather than a breakthrough moment this week, and it is important to say that plainly rather than overstate it.
Our own search for a cure this week
Every day, PF-Atlas runs its own discovery engine, a piece of software we built that combines a genetic-algorithm solver with an AI literature scan. Its job is not to summarize other people's research. Its job is to simulate combinations of existing, already-approved or already-studied drugs, including drugs originally developed for other diseases entirely, and score them on how well they might work together against IPF. Think of it as a very fast, very systematic way of asking: what if we mixed this drug with that one, and added a third? This week the solver completed 18 simulation runs and produced several outputs worth noting. These are computer-generated hypotheses only. They have not been tested in people, and some have not been tested in animals for this purpose. They are directions for researchers to investigate, not treatments anyone can access. The solver's top five candidate drugs highlighted this week are: Sobetirome (also called GC-1), an inhaled compound that selectively activates a thyroid hormone receptor in the lungs; Panobinostat at a low inhaled dose, a drug already used in blood cancer that blocks enzymes called HDACs involved in gene regulation; a fragment of a protein called Jagged-1, which activates a repair signaling pathway called Notch; ZZW-115, which targets a stress-response protein called NUPR1 that helps fibrosis survive under pressure; and LTI-3114, another inhaled thyroid hormone receptor activator. The solver also added four new candidates to its research pool this week: a TGF-beta degrader inspired by a plant compound called Verbascoside, Verbascoside itself, Nerandomilast modeled specifically for its effects on lung stem cell behavior, and an inhaled form of Tanshinone IIA delivered in tiny lipid particles. No cross-disease candidates were identified this week and no fully formed hypotheses were filed, which reflects an honest week of computational groundwork rather than a headline result. The solver's current best-performing formula combines five agents: a WNT pathway activator (RSPO3), an ECM remodeling inhibitor (targeting the scaffolding that holds scar tissue together), a HOPX activator to push cells toward a healthy lung identity, curcumin targeting inflammation pathways TLR4 and NLRP3, and a microRNA inhibitor called miR-34a inhibitor. This five-drug combination scored 99 out of 100 on our model's simulated lung function metric. To be very clear: a score of 99 in our model means the software predicts this combination could work well based on the biology it has read. It does not mean it works in patients. It does not mean it is safe. It means our computer thinks it is worth a scientist's serious attention. We publish it transparently because we believe the fastest path to helping patients is sharing these hypotheses openly so the broader research community can evaluate them.
Inside the PF-Atlas lab
- Sobetirome (GC-1), Inhaled TRβ-Selective Thyromimetic
- Panobinostat (inhaled, low-dose), HDAC Class I/II inhibitor
- Recombinant Jagged-1 Ectodomain Fragment (Jag1-Fc)
- ZZW-115 / Trifluoperazine-class NUPR1 Inhibitor (e.g., ZZW-115)
- LTI-3114 (Selective Thyroid Hormone Receptor Beta-2 Agonist, Inhaled)
Everything here is PF-Atlas computer model output, a hypothesis to guide researchers. It is not clinical evidence and not a treatment anyone can take.
Sources this week
- Clinical detection and attribution of common disease in exposed populations. · Diagnosis (Berlin, Germany) 2026 PMID 42909490 on PubMed ↗
- TOMM5-glycolysis-Mlxipl axis: A novel mechanistic insight into idiopathic pulmonary fibrosis. · Biochimica et biophysica acta. Molecular basis of disease 2026 PMID 42927871 on PubMed ↗
- Emergency granulopoiesis is associated with intermittent hypoxemia in idiopathic pulmonary fibrosis. · American journal of respiratory and critical care medicine 2026 PMID 42921747 on PubMed ↗
- Bridging the GAP: Prognostic stratification by longitudinal FVC changes in IPF. · Journal of the Chinese Medical Association : JCMA 2026 PMID 42921867 on PubMed ↗
- A less invasive alternative to fenestration for selected localized postoperative empyema with persistent air leak: prolonged open drainage using a large-sized cut tube in two patients. · General thoracic and cardiovascular surgery cases 2026 PMID 42920195 on PubMed ↗
- Cross-ancestry evaluation of idiopathic pulmonary fibrosis genetic risk variants. · The European respiratory journal 2026 PMID 42919642 on PubMed ↗
- Predicting Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathy-associated Interstitial Lung Disease: A Machine Learning Approach Integrating Quantitative CT and Clinical Features. · Respiratory medicine 2026 PMID 42918262 on PubMed ↗
- Mesothelial plasticity regulates lung mechanical homeostasis in regeneration and fibrosis. · Developmental cell 2026 PMID 42914979 on PubMed ↗
- Interstitial Lung Diseases treatment prescription practices among pulmonologists in India: A prospective multicentre observational study (India-ILD care study). · PloS one 2026 PMID 42912795 on PubMed ↗
- Pulmonary diffusion capacity to select patients for echocardiographic evaluation of pulmonary hypertension in interstitial lung disease: Impact of interstitial lung disease phenotype. · Respiratory investigation 2026 PMID 42913275 on PubMed ↗
- Dynamic chest radiography-derived low-motion area ratio as a potential exploratory quantitative biomarker of idiopathic pleuroparenchymal fibroelastosis. · Respiratory investigation 2026 PMID 42913273 on PubMed ↗
- Institutional patterns in diagnosis and antifibrotic-era treatment uptake for IPF and PPF across U.S. centers. · PloS one 2026 PMID 42911924 on PubMed ↗
- Lung Transplantation for Interstitial Lung Disease: A Northern Ireland Cohort Study. · Pulmonary therapy 2026 PMID 42911543 on PubMed ↗
- Effectiveness of tocilizumab monotherapy for IgG4-related disease-like features caused by idiopathic multicentric Castleman's disease: a case-based review. · Rheumatology international 2026 PMID 42911255 on PubMed ↗
- Phase 3 Antifibrotic-Directed Therapy Outcomes in Idiopathic Pulmonary Fibrosis: Beyond FVC Decline. · Lung 2026 PMID 42907709 on PubMed ↗
- PIEZO1 promotes YAP/TEAD-dependent profibrotic signaling in POSTN-enriched lung fibroblast activation. · Biochemical and biophysical research communications 2026 PMID 42727476 on PubMed ↗
- The role of inflammation in the pathogenesis of pulmonary fibrosis: mechanisms and treatment implications. · The European respiratory journal 2026 PMID 42660607 on PubMed ↗
- Nailfold videocapillaroscopy as a diagnostic clue in interstitial lung disease: differentiating idiopathic from autoimmune patterns in a Caucasian cohort. · Reumatismo 2026 PMID 42922420 on PubMed ↗
- Reply: Comparative Clinical Outcomes of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Five-Year Real-Life Study. · Thoracic research and practice 2026 PMID 42902608 on PubMed ↗
- Translation, Cultural Adaptation, and Validation of the Turkish Version of the St George's Respiratory Questionnaire for Idiopathic Pulmonary Fibrosis (SGRQ-I). · Thoracic research and practice 2026 PMID 42902607 on PubMed ↗
This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.